UBS Group
ZURA icon

UBS Group’s Zura Bio ZURA Stock Holding History

UBS Group’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Buy
265,314
+24,287
+10% +$116K ﹤0.01% 5331
2026
Q1 		$1.43M Sell
241,027
-229,513
-49% -$1.39M ﹤0.01% 5258
2025
Q4 		$2.47M Buy
470,540
+165,211
+54% +$653K ﹤0.01% 4768
2025
Q3 		$1.32M Buy
305,329
+274,118
+878% +$493K ﹤0.01% 5323
2025
Q2 		$32.8K Sell
31,211
-27,642
-47% -$33K ﹤0.01% 8100
2025
Q1 		$75.9K Sell
58,853
-6,439
-10% -$10.2K ﹤0.01% 7258
2024
Q4 		$163K Buy
65,292
+44,328
+211% +$158K ﹤0.01% 6585
2024
Q3 		$85.1K Buy
20,964
+14,815
+241% +$55.3K ﹤0.01% 6467
2024
Q2 		$21.5K Sell
6,149
-11,083
-64% -$45.2K ﹤0.01% 7258
2024
Q1 		$44.3K Buy
+17,232
New +$61.1K ﹤0.01% 6567
2023
Q2 		– Sell
-1,162
Closed -$17.3K – 9775
2023
Q1 		$17.3K Sell
1,162
-674
-37% -$8.22K ﹤0.01% 7188
2022
Q4 		$18.7K Hold
1,836
– – ﹤0.01% 7716
2022
Q3 		$18K Hold
1,836
– – ﹤0.01% 7545
2022
Q2 		$18K Sell
1,836
-784
-30% -$7.79K ﹤0.01% 7041
2022
Q1 		$26K Buy
+2,620
New +$25.8K ﹤0.01% 7159

Other funds holding ZURA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

UBS Group's ZURA Position: Q2 2026 in Review

UBS Group increased its Zura Bio (ZURA) stake by 10% in Q2 2026, buying an estimated $116K and bringing the position to 265,314 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #5331.

UBS Group first reported a position in ZURA in Q1 2022 and has held it in 15 quarters since. The position peaked at $2.47M in Q4 2025. 95 funds tracked by Wall St. Rank hold ZURA as of Q2 2026.

  • UBS Group held 265,314 shares of Zura Bio worth $1.57M as of Q2 2026.
  • UBS Group bought 24,287 Zura Bio shares in Q2 2026, an estimated $116K.
  • Zura Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5331 holding.
  • UBS Group first reported a position in Zura Bio in Q1 2022 and has held it in 15 quarters since.
  • UBS Group's Zura Bio position peaked at $2.47M in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Zura Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.